Ganesh R, Pawlowski CF, O’Horo JC, et al. - Using bamlanivimab for treating high-risk patients with mild to moderate COVID-19 was linked with a statistically significant lower rate of hospitalization, ICU admission, and mortality when compared with those receiving usual care.

• Comparison was performed between 2,335 patients who received single-dose bamlanivimab infusion and a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states.

• Hypertension (54.2%), BMI greater than or equal to 35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%) were included as high-risk characteristics.

• Lower all-cause hospitalization rates were recorded at days 14 (1.5% vs 3.5%), 21 (1.9% vs 3.9%), and 28 (2.5% vs 3.9%) among patients who received bamlanivimab.

• Patients who received bamlanivimab also had lower intensive care unit (ICU) admission rates at days 14 (0.14% vs 1%), 21 (0.25% vs 1%), and 28 (0.56% vs.1.1%) and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%), and 28 (0.11% vs. 0.44%).

• Adverse events were uncommon with bamlanivimab.